Skip to main content
Top
Published in: Tumor Biology 5/2013

01-10-2013 | Research Article

Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer

Authors: Jun-Jun Qiu, Jun-Jie Guo, Tian-Jiao Lv, Hong-Yan Jin, Jing-Xin Ding, Wei-Wei Feng, Ying Zhang, Ke-Qin Hua

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

Altered expression of centromere protein-A (CENP-A) is observed in various types of human cancers. However, the clinical significance and pathological role of CENP-A in epithelial ovarian cancer (EOC) remains unclear. The main objective of this investigation was to clarify the relationships between CENP-A expression and the clinicopathological features of patients with EOC. Real-time quantitative PCR and Western blot were performed to examine CENP-A expression in 20 pairs of fresh-frozen EOC tissues and corresponding noncancerous tissues. Using immunohistochemistry, we performed a retrospective study of the CENP-A expression levels on 120 archival EOC paraffin-embedded samples. Prognostic outcomes correlated with CENP-A were examined using Kaplan–Meier analysis and Cox proportional hazards model. Our results showed that the expression levels of CENP-A mRNA and protein in EOC tissues were both significantly higher than those in noncancerous tissues. By immunohistochemistry, the data revealed that high CENP-A expression was significantly correlated with pathological grade (P = 0.02) and International Federation of Gynecology and Obstetrics stage (P = 0.006). Consistent with these results, we found that high expression of CENP-A was significantly correlated with poor survival in EOC patients (P < 0.001). Furthermore, Cox regression analyses showed that CENP-A expression was an independent predictor of overall survival. Our data suggest that CENP-A could play an important role in EOC and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of EOC.
Literature
3.
go back to reference Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320–8. doi:10.1158/1078-0432.CCR-10-0974.PubMedCentralCrossRefPubMed Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320–8. doi:10.​1158/​1078-0432.​CCR-10-0974.PubMedCentralCrossRefPubMed
5.
go back to reference Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246:190–200. doi:10.1016/j.canlet.2006.02.018.CrossRefPubMed Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246:190–200. doi:10.​1016/​j.​canlet.​2006.​02.​018.CrossRefPubMed
8.
go back to reference Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003;63:3511–6.PubMed Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003;63:3511–6.PubMed
10.
go back to reference McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012;14:R72. doi:10.1186/bcr3181.PubMedCentralCrossRefPubMed McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012;14:R72. doi:10.​1186/​bcr3181.PubMedCentralCrossRefPubMed
13.
go back to reference Wang M, He Y, Shi L, Shi C. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32:171–7.PubMed Wang M, He Y, Shi L, Shi C. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32:171–7.PubMed
Metadata
Title
Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer
Authors
Jun-Jun Qiu
Jun-Jie Guo
Tian-Jiao Lv
Hong-Yan Jin
Jing-Xin Ding
Wei-Wei Feng
Ying Zhang
Ke-Qin Hua
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0860-6

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine